ersistent infection with high-risk human papillomavirus (HPV) is the causative agent for cervical cancer (1, 2). Testing for HPV DNA provides better protection against cervical cancer and its precursors, i.e., high-grade cervical intraepithelial neoplasia (CIN), compared to cytology (3-7). For primary cervical cancer screening, it is crucial that the HPV assays that are used are clinically validated to ensure optimal distinction between HPV infections associated with CIN grade 2 or worse (CIN2ϩ) and clinically irrelevant transient HPV infections (8, 9) .
P
ersistent infection with high-risk human papillomavirus (HPV) is the causative agent for cervical cancer (1, 2) . Testing for HPV DNA provides better protection against cervical cancer and its precursors, i.e., high-grade cervical intraepithelial neoplasia (CIN), compared to cytology (3) (4) (5) (6) (7) . For primary cervical cancer screening, it is crucial that the HPV assays that are used are clinically validated to ensure optimal distinction between HPV infections associated with CIN grade 2 or worse (CIN2ϩ) and clinically irrelevant transient HPV infections (8, 9) .
A variety of HPV DNA detection assays are currently considered clinically validated with cervical scraping specimens for cervical cancer screening purposes. Validation has been based on either data from large prospective screening trials (i.e., high-risk HPV Hybrid Capture 2 [HC2] and GP5ϩ/6ϩ PCR) (3, 5, 6, 10) or cross-sectional clinical equivalence analyses according to international guidelines (8, 9) for HPV DNA test requirements (11) (12) (13) . In addition to clinician-based sampling, HPV self-sampling is an emerging effective strategy for cervical screening. Offering HPV testing on self-collected cervicovaginal specimens reattracts a substantial number of nonattendees into the screening program and effectively detects CIN2ϩ (14, 15) . However, standardization of the collection device, HPV test, and sample preparation protocols is important to minimize variations in the CIN2ϩ sensitivity and specificity of HPV self-sampling (reviewed in reference 16). It must be realized that the use of an HPV test that is clinically validated for cervical scraping specimens does not automatically result in high clinical accuracy when it is applied to self-collected specimens (17) . Therefore, a separate analysis of the candidate HPV test with self-collected samples, relative to its performance with cervical scraping specimens, is important to ensure suitability for HPV self-sampling. Given the potential variations in target cell yields between different self-samplers (16) , such a comparative accuracy analysis ideally should be performed for each selfsampler type, in order to determine the best combination of selfsampler and validated HPV test.
Most assays validated for cervical screening purposes use PCRbased assays targeting regions within the HPV E1 or L1 open reading frames (11, 13, 18) . However, malignant progression of cervical lesions is often associated with viral DNA integration into the genome of the host cell (19) . Integration often takes place between the E1 and L1 regions, with a probability of interruption of the PCR target region. This may result in nondetection of HPV by E1-or L1-based assays (2, 19) . A novel real-time PCR assay that targets the E7 region of high-risk HPV types is the HPV-Risk assay (SelfScreen BV, Amsterdam, The Netherlands). This assay was designed to detect clinically relevant infections with a total of 15 high-risk HPV types (i.e., HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68), chosen on the basis of their presence in other clinically validated HPV PCR assays (11, 13, 18) , supplemented with types found to be stably integrated in cervical carcinoma cell lines. Compared to currently clinically validated HPV assays, this assay covers an extra type (i.e., HPV67), which was added on the basis of the following criteria: (i) it belongs to the alpha 9 species, which, in addition to HPV67, contains only established high-risk HPV types that are classified as class 1 carcinogens (20) , (ii) it has been demonstrated in cervical carcinomas and several cases of cervical cancers worldwide (20, 21) , and (iii) it has been found to be stably integrated in a cervical cancer cell line (22) . The HPV-Risk assay simultaneously reports on a pool of non-HPV16/HPV18 high-risk HPV types and provides individual results for HPV16 and HPV18, the two most oncogenic genotypes (23, 24) .
In this study, we report on the analytical and clinical performance of the HPV-Risk assay. The clinical analyses involved guideline-directed clinical validation and reproducibility analyses with cervical scraping specimens (8, 9) . Furthermore, we compared the performance of the HPV-Risk assay with self-collected (cervico)vaginal samples with the performance with concomitantly clinician-obtained cervical scraping specimens. The selfcollected samples were obtained with two different self-samplers, i.e., a brush-based device (25) and a lavage-based device (26) .
MATERIALS AND METHODS
HPV-Risk assay. The HPV-Risk assay (Self-Screen BV, Amsterdam, The Netherlands) is a multiplex real-time PCR-based assay designed for the clinical detection of high-risk HPV DNA in various clinical sample types. The HPV-Risk assay targets an ϳ150-bp fragment of the E7 region of 15 (probably) high-risk HPV types (i.e., HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68) and detection is by hydrolysis probes with 3 spectrally unique fluorescent dyes, each representing different (pools of) targets. The three different (pools of) targets are HPV16, HPV18, and the 13 other high-risk HPV types combined. The human ␤-globin gene is detected in a fourth channel using a probe labeled with a different fluorescent dye and serves as internal control to determine the quality of the sample DNA and the presence of potential inhibitory substances. The HPV-Risk assay uses 5-l input of the sample DNA and runs on an ABI7500 Fast Real-Time PCR system (Applied Biosystems) or an equivalent real-time PCR system with a run time of 1 h, according to the manufacturer's instructions. A sample was considered HPV positive when threshold cycle (C T ) values for HPV16, HPV18, and/or other HPV types were Ͻ36. In cases in which no HPV signals were obtained, the sample was considered HPV negative when the C T value for the ␤-globin target was Ͻ33 (e.g., equals ϳ25 cells per reaction). A sample was scored as invalid when the C T value for HPV was Ͼ36 and that for ␤-globin was Ͼ33.
Analytical sensitivity and specificity analyses. DNAs from plasmids containing the complete genomes of HPV genotypes 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 45 , 51, 52, 53, 56, 58, 59, 61, 66, 67, 68, and 70 were used as amplification targets in analytical experiments. To assess analytical sensitivity, serial 10-fold plasmid dilutions (ranging from 4.6 ϫ 10 6 to 4.6 ϫ 10 Ϫ1 copies per reaction) of the 15 targeted HPV types were prepared in a background of 100 ng/reaction human placental DNA (SigmaAldrich), in order to mimic cervical specimens. The analytical sensitivities were tested in 6-fold replications and scored positive when at least 5/6 replicates tested positive. To assess analytical specificity, plasmid DNAs representing 46,000 copies of nontargeted HPV types (i.e., HPV6, -11, -26, -40, -42, -43, -53, -61, and -70) per reaction were used in a background of 300 pg human placental DNA (approximately 60 genome equivalents). Nonspecific targets giving positive signals in the HPV-Risk assay were further diluted to determine the limit of detection. In addition, DNA representing 10,000 copies of each of the three most common vaginal microorganisms (Chlamydia trachomatis, Neisseria gonorrhea, and Candida albicans) was analyzed.
DNA extraction. DNA was extracted from clinical specimens using an automated silica-based extraction system (Macherey-Nagel, Düren, Germany), according to the instructions of the manufacturer, and DNA was stored at Ϫ20°C until further use. All PCR assays were performed with aliquots from the same DNA isolate.
High-risk HPV GP5؉/6؉ PCR (reference assay). Standardized highrisk HPV DNA detection by the clinically validated GP5ϩ/6ϩ PCR with enzyme immunoassay (EIA) read out was performed as described previously (18) . Separate ␤-globin PCR testing for sample quality control was performed as described by de Roda Husman et al. (27) . Input in the GP5ϩ/6ϩ PCR and ␤-globin-PCR assays was 10 l of the DNA isolate. Genotyping of the GP5ϩ/6ϩ PCR products was performed with a beadbased array for high-risk HPV types (28) and a reverse line blot (RLB) analysis for low-risk types (18) .
Cervical scraping specimens for clinical validation and reproducibility analyses. DNA isolates from a total of 1,444 clinician-obtained cervical scraping specimens collected in PreservCyt medium (Hologic) in a population-based screening setting in the Utrecht and North Holland region of The Netherlands were used for clinical validation and reproducibility analyses. All scraping specimens were tested with both the high-risk HPV GP5ϩ/6ϩ PCR assay (serving as a reference) and the HPV-Risk assay. The scraping specimens included 70 samples from women with histologically confirmed CIN2ϩ (i.e., 29 CIN2 cases, 37 CIN3 cases, and 4 squamous cell carcinoma [SCC] cases) for clinical sensitivity analysis. Of these samples, 50 (71%) had abnormal cytological findings. The remaining 20 samples (29%) were cytomorphologically normal but tested HPV positive by the high-risk HPV GP5ϩ/6ϩ PCR assay. The median age at diagnosis was 39 years (range, 30 to 60 years). Another 824 cervical scraping specimens were also used for clinical specificity analysis, representing consecutive samples from women with normal cytological findings who were without evidence of CIN2ϩ in up to 2 years of follow-up monitoring. The median age of these women was 41 years (range, 30 to 60 years). For analysis of intralaboratory reproducibility over time and interlaboratory agreement, a final series of 550 cervical scraping specimens was used. These represented a selected set, of which 30% (165/550 specimens) tested positive in the high-risk HPV GP5ϩ/6ϩ PCR assay. Of these scraping specimens, two portions were independently analyzed, after a Ͼ8-week interval, by different technicians in the Department of Pathology, VU University Medical Center (Amsterdam, The Netherlands) (hereafter referred to as laboratory 1), and a third portion was tested blindly in the Department of Medical Microbiology, Maastricht University Medical Center (Maastricht, The Netherlands) (hereafter referred to as laboratory 2). All portions were analyzed using different batches of the HPV-Risk assay.
Self-sampled specimens and corresponding clinician-collected cervical scraping specimens. DNA isolated from two types of self-sampled specimens from women visiting an outpatient clinic (25, 26) were used to compare the performance of the HPV-Risk assay with these sample types relative to that of the HPV-Risk assay with the corresponding cliniciancollected cervical scraping samples. For comparison, the high-risk HPV GP5ϩ/6ϩ PCR assay was also performed for the self-sampled specimens. The two series of self-sampled specimens included 62 Delphi Screener (Delphi Biosciences, Scherpenzeel, The Netherlands) cervicovaginal lavage samples, with concomitantly clinician-collected cervical scraping specimens collected in SurePath medium (BD), which were described by Brink et al. (26) , and 112 self-collected vaginal brush samples collected using a VibaBrush (Rovers Medical Devices, Oss, The Netherlands), with concomitantly clinician-collected cervical scraping specimens collected in PreservCyt medium, which were described by Dijkstra et al. (25) .
Statistical analyses. Testing of the HPV-Risk assay was performed blinded for GP5ϩ/6ϩ PCR results and cytological and histological outcomes, and data were correlated subsequently. The clinical sensitivity and specificity values for the HPV-Risk assay with cervical scraping specimens were compared with those for the GP5ϩ/6ϩ PCR assay using a noninferiority score test, as described by Tang et al. (29) , with a relative sensitivity threshold for CIN2ϩ of 90% and a relative specificity threshold for CIN2ϩ of 98% (8) . For the intralaboratory reproducibility and interlaboratory agreement analyses of the HPV-Risk assay with cervical scraping specimens, the agreement and kappa values for samples with valid test results were determined. The 95% lower confidence bounds of the intralaboratory reproducibility and interlaboratory agreement values should both be Ն87%, with kappa values of Ͼ0.5 (8) . For comparison of the HPV-Risk assay for self-and clinician-collected specimens and comparison of the HPV-Risk assay with the GP5ϩ/6ϩ PCR assay for selfcollected specimens, overall agreement and kappa values were determined for samples with valid test results.
Interassay and interspecimen genotype agreement was determined among HPV-positive samples. For this purpose, genotype results for GP5ϩ/6ϩ PCR products were categorized as (i) HPV16, (ii) HPV18, (iii) other HPV types, including HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and/or -68 or (iv) HPV X. HPV X was scored when samples tested positive with the GP5ϩ/6ϩ PCR EIA but yielded no genotype with the bead-based genotyping assay. Concordant genotype findings were defined as complete agreement between the two assays, compatible findings as having at least one genotype category in common, and discordant findings as no similarity between detected genotype categories. For calculations, we used SPSS (version 20) and Stata software. P values of Ͻ0.05 were considered statistically significant.
RESULTS
Analytical performance of the HPV-Risk assay. The analytical sensitivity of the HPV-Risk assay was evaluated with 10-fold dilution series of cloned HPV genotypes (i.e., HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68). All targeted types demonstrated highly specific signals in the respective channel of detection (i.e., HPV16 in the HPV16 channel, HPV18 in the HPV18 channel, and the other targeted types in the "other HPV" channel). The limit of detection of the HPV-Risk assay for the targeted HPV types ranged from 460 copies/reaction for genotypes 16, 18, and 56 to 46,000 copies/reaction for genotypes 52, 58, 66, and 67 ( Table 1) .
The analytical specificity of the HPV-Risk assay was assessed by testing cloned HPV DNA of genotypes 6, 11, 26, 40, 42, 43, 53, 61, and 70 using a high-copy number input of 46,000 copies/reaction. Only HPV70 displayed cross-reactivity, reflected by a signal in the other HPV channel. Further dilution revealed that the HPV70 genotype is detected at a minimal input of 17,000 copies/reaction. No cross-reactivity was observed with Chlamydia trachomatis, Neisseria gonorrhea, or Candida albicans.
Clinical validation of the HPV-Risk assay with clinician-collected cervical scraping specimens. For clinical sensitivity and specificity analyses of the HPV-Risk assay, a series of 894 cervical scraping specimens (70 from women with CIN2ϩ and 824 from women without evidence of CIN2ϩ) were tested, of which 99.9% (893/894 samples) gave valid test results (Table 2) . One sample, from a woman diagnosed with CIN2, repeatedly tested invalid in the HPV-Risk assay. The clinical sensitivity for CIN2ϩ of the HPV-Risk assay was 97.1% (95% confidence interval [CI], 89.1 to 99.3%; 67/69 samples) ( Table 2) , and the clinical specificity for CIN2ϩ was 94.3% (95% CI, 92.5 to 95.7%; 777/824 samples) ( Table 2 ). For comparison, these figures were 97.1% (95% CI, 89.1 to 99.3%; 67/69 samples) and 94.1% (95% CI, 92.2 to 95.5%; 775/824 samples), respectively, for the GP5ϩ/6ϩ PCR assay. Both the clinical sensitivity and the specificity for CIN2ϩ of the HPVRisk assay were noninferior to those of the GP5ϩ/6ϩ PCR assay (noninferiority score test, P ϭ 0.006 and 0.0003, respectively).
In the sensitivity and specificity analyses, 106 samples tested positive with both assays. Of the double-positive (HPV-Risk assay and GP5ϩ/6ϩ PCR assay) samples, 92.5% (98/106 samples) revealed concordant and 7.5% (8/106 samples) compatible genotyping results (see Table S1 in the supplemental material). Among the two cases with discrepant test results, one woman with CIN3 tested positive for other HPV with the HPV-Risk assay and negative with the GP5ϩ/6ϩ PCR assay, and one woman with CIN2 tested negative with the HPV-Risk assay but positive with the GP5ϩ/6ϩ PCR assay (HPV18 and HPV52). Another woman with CIN2 tested negative with both the HPV-Risk assay and the GP5ϩ/6ϩ PCR assay. Sixteen women without evidence of CIN2ϩ had discrepant results, nine of whom tested GP5ϩ/6ϩ PCR positive/HPV-Risk assay negative and seven tested GP5ϩ/6ϩ PCR negative/HPVRisk assay positive. Of the nine GP5ϩ/6ϩ PCR-positive/HPVRisk assay-negative samples, 7 had signals just above the EIA threshold (all single infections, involving HPV16, -33, -35, -45, -59, -66, and HPV X). The remaining two samples had EIA values clearly above the threshold and contained HPV39 and HPV58. The seven GP5ϩ/6ϩ PCR-negative/HPV-Risk assay-positive samples were all positive for other HPV; four had signals just above the HPV-Risk assay threshold. Reverse line blot analysis of GP5ϩ/6ϩ PCR products revealed that 5 of the 7 samples contained HPV types reactive in the HPV-Risk assay but not detectable by high-risk HPV GP5ϩ/6ϩ PCR (i.e., HPV67 [n ϭ 2] and HPV70 [n ϭ 3]). An additional sample showed a reverse line blot signal for HPV39 but, based on the EIA read out, this specimen was below the threshold for scoring the sample as high-risk HPV positive. Only one sample showed no genotype by reverse line blot analysis.
Intralaboratory reproducibility and interlaboratory agreement of HPV-Risk assay results. The intralaboratory reproducibility of the HPV-Risk assay was determined with 550 cervical scraping specimens, of which 533 also had sufficient material for the interlaboratory agreement analysis. Valid HPV-Risk assay results were obtained for 547/550 samples (99.5%) tested in both series performed in laboratory 1 and for 531/533 samples (99.6%) tested in laboratory 2 ( Table 3 ). The intralaboratory reproducibility was 99.5% (95% CI, 98.6 to 99.8%; 544/547 samples), with a kappa value of 0.99. The interlaboratory agreement was 99.2% (95% CI, 98.6 to 99.8%; 527/531 samples), and the kappa value was 0.98. Of the samples positive with the HPV-Risk assay in both runs in laboratory 1, 99.4% (154/155 samples) had concordant genotyping results and 0.6% (1/155 samples) compatible genotyping results (see Table S2A in the supplemental material). Also, the interlaboratory genotyping agreement was high, i.e., 97.2% (141/145 samples) had concordant results and 2.8% (4/145 samples) compatible results (see Table S2B in the supplemental material).
HPV-Risk assay with self-collected cervicovaginal lavage specimens. The agreement between the results of the HPV-Risk assay with self-collected cervicovaginal lavage specimens and concomitantly clinician-collected cervical scraping specimens was determined for a set of women (n ϭ 62) visiting an outpatient clinic. In addition, GP5ϩ/6ϩ PCR was performed on the self-collected specimens for comparison (Table 4 ; also see Table S1 in the supplemental material). Of the samples with valid HPV-Risk assay results, 60.7% (37/61 samples) of the self-collected samples and 68.0% (34/50 samples) of the clinician-obtained cervical scraping Invalid  1  1  1  1  Negative  9  13  22  22  22  Positive  3  1  12  16  1  15  16  Total  12  15  12  39  24  15  39   CIN2ϩ  Negative  1  1  2  1  1  2  Positive  21  21  21  21  Total  1  22  23  1  22  23   Overall  Invalid  1  1  1  1  Negative  9  14  1  24  23  1  24  Positive  3  1  33  37  1  36  37  Total  12  16  34  62  25  37  62 a Agreement between HPV-Risk assay results for self-collected and clinician-collected specimens was as follows: ՅCIN1, 96% (95% CI, 77 to 99%), 25/26 samples, kappa ϭ 0.92; CIN2ϩ, 96% (95% CI, 75 to 99%), 22/23 samples, kappa ϭ 0.65; overall, 96% (95% CI, 85 to 99%), 47/49 samples, kappa ϭ 0.90. b Agreement between HPV-Risk assay and GP5ϩ/6ϩ PCR assay results was as follows: ՅCIN1, 97% (95% CI, 84 to 100%), 37/38 samples, kappa ϭ 0.95; CIN2ϩ, 96% (95% CI, 75 to 99%), 22/23 samples, kappa ϭ 0.65; overall, 97% (95% CI, 88 to 99%), 59/61 samples, kappa ϭ 0.93.
specimens scored HPV positive with the HPV-Risk assay (Table  4 ). The overall agreement in HPV-Risk assay findings between the two sampling methods was 95.9% (95% CI, 85.1 to 99.0%; 47/49 samples), with a kappa value of 0.90. Similar agreement figures were found after stratification for CIN2ϩ or when comparing HPV-Risk assay results with GP5ϩ/6ϩ PCR assay results for selfcollected lavage samples (Table 4) . Also the genotype agreement between HPV-Risk assays with the two sample types was high; 97.0% (32/33 samples) had identical and 3.0% (1/33 samples) compatible types (see Table S3A in the supplemental material).
One woman with CIN3 who tested negative with the HPV-Risk assay with the self-collected sample but HPV16 positive with the clinician-obtained scraping specimen displayed a HPV16 signal in the self-collected sample just below the HPV-Risk assay threshold. A women with ՅCIN1 scored positive with the HPV-Risk assay (other HPV) with the self-collected sample and negative with the clinician-obtained scraping specimen. For this sample, GP5ϩ/6ϩ PCR also yielded negative results for the self-collected sample. HPV-Risk assay with self-collected vaginal brush specimens. The agreement between the HPV-Risk assay results for self-collected vaginal brush specimens and concomitantly clinician-obtained cervical scraping specimens for the same women was determined for a set of 112 women. For comparison, self-collected specimens were also tested with the GP5ϩ/6ϩ PCR assay (Table 5 ; also see Table S1 in the supplemental material). The HPV-Risk assay scored 61.6% of the self-collected samples (69/112 samples) and 65.4% of the clinician-obtained scraping specimens (70/107 samples) positive (Table 5) . Overall agreement in HPV-Risk assay findings between the two sampling methods was 91.6% (95% CI, 84.6 to 95.6%; 98/107 samples), with a kappa value of 0.82. Similar agreement figures were found after stratification for CIN2ϩ or when comparing HPV-Risk assay results with GP5ϩ/6ϩ PCR assay results for self-collected brush samples. Genotype agreement between HPV-Risk assays with the two sample types was high; 87.7% (57/65 samples) had identical types and 12.3% (8/65 samples) compatible types (see Table S3B in the supplemental material). Nine women had discrepant HPV-Risk assay results for the self-collected and clinician-obtained samples (3 CIN2ϩ cases and 6 ՅCIN1 cases). For six of the women, the HPV status for the self-collected specimen was confirmed by the GP5ϩ/6ϩ PCR assay (three HPV-negative cases and three HPV-positive cases. i.e., single infections, involving HPV16, HPV52, and HPV X). Furthermore, one GP5ϩ/6ϩ PCR-negative/HPV-Risk assay-positive sample tested positive for other HPV but was just above the assay threshold, and two GP5ϩ/6ϩ PCR-positive/HPV-Risk assaynegative samples displayed signals in the HPV-Risk assay just below the assay thresholds for the genotypes detected with GP5ϩ/6ϩ PCR (i.e., HPV16 and other HPV, representing HPV33 by genotyping of the GP5ϩ/6ϩ PCR product).
DISCUSSION
In this study, we reported on the analytical and clinical performance of a novel E7-based real-time PCR-based assay, i.e., the HPV-Risk assay. When applied to cervical scraping specimens, the HPV-Risk assay displayed similar clinical sensitivity and specificity for CIN2ϩ as did the high-risk HPV (L1-based) GP5ϩ/6ϩ PCR. Together with the observed high intralaboratory reproducibility and interlaboratory agreement figures, with lower confidence bounds of Ͼ87%, and the kappa values of Ͼ0.5, these findings indicate that the HPV-Risk assay can be considered clinically validated for cervical cancer screening purposes, according to the international guidelines for HPV test requirements (8) .
We also found a high agreement value for HPV (genotype) detection in self-collected and clinician-collected specimens, both for brush-based and lavage-based self-collected samples. These data support the utility of the HPV-Risk assay with these sample types. A limitation might be the number of women and the study population (i.e., outpatient clinic based), which might have hampered accurate assessment of the clinical performance of the HPVRisk assay with self-collected specimens. Clinical validation of HPV assays for use with self-collected samples is important, given that variations in the clinical performance of HPV testing with self-collected samples have been described, likely reflecting the use of different combinations of HPV tests and collection devices (reviewed in references 16 and 30-32) . For example, in a study in which two HPV tests were performed, one (Cervista) was clearly inferior with self-collected samples, compared with clinician-collected samples, in terms of CIN2ϩ detection, whereas the other (11-13, 34, 35) , the HPV-Risk assay does not require specialized equipment for sample preparation, DNA extraction, or amplification. The assay can run on different real-time PCR platforms (e.g., Life Technologies and Bio-Rad) and is compatible with various collection media and different (automatic) DNA extraction procedures, as shown in this study.
In this study, a total of 127 women with CIN2ϩ were tested (i.e., 70 clinician-obtained cervical scraping specimens, 23 selfcollected lavage specimens and concomitantly clinician-obtained cervical scraping specimens, and 34 self-collected brush specimens and concomitantly clinician-obtained cervical scraping specimens) with both the HPV-Risk assay and the GP5ϩ/6ϩ PCR assay. Discrepant assay results were obtained for only six women, including one CIN2 case with an invalid HPV-Risk assay result. Three women tested GP5ϩ/6ϩ PCR positive/HPV-Risk assay negative, i.e., one CIN2 case (HPV18 and HPV52) and two CIN3 cases (HPV16 and HPV X, i.e., a possible variant not detected with the genotyping assay). The latter two samples did yield signals just below the HPV-Risk assay threshold for HPV16 and HPV18/other HPV, respectively. The remaining two GP5ϩ/6ϩ PCR-negative/ HPV-Risk assay-positive cases both tested positive for other HPV and included a CIN2 case and a CIN3 case. Discrepant findings for control women without disease predominantly involved signals just above the threshold of either assay for all sample types. Collectively, these data suggest that these discrepant results are predominantly related to sampling issues for specimens with low viral loads.
Some degree of cross-reactivity with HPV70 at high copy numbers was observed. The latter can be explained by the high level of sequence homology (Ͼ95%) between genotypes 39, 68, and 70 from the alpha 7 clade in the targeted region of the E7 gene (data not shown). However, since HPV70 is considered probably carcinogenic, on the basis of epidemiological, phylogenetic, and functional studies, and the prevalence of HPV70 in the population is very low, the impact of this cross-reactivity on the performance of the assay will be very low (20, 36, 37) .
In conclusion, the HPV-Risk assay meets the cross-sectional clinical and reproducibility criteria of the international guidelines for HPV test requirements and can be considered clinically validated for cervical screening purposes. The compatibility of the HPV-Risk assay with self-collected cervicovaginal lavage-and brush-based specimens supports its utility for HPV self-sampling.
